摘要
我们研究DTPA-bis(蛋氨酸)的潜在作用,它是一种靶标特定的氨基酸探针,可使用多峰性成像技术检测在增殖肿瘤中过度表达的L-型氨基酸转运蛋白(LAT1)。它的配体,DTPA-bis(Met)容易转化为镧系配合物,且使用多峰性成像能够发现其靶向癌细胞。DTPA-bis(Met)配合物可被合成和被质谱表征。MR纵向弛豫, r1=4.067 ± 0.31 mM-1s-1 和横向弛豫,r2= 8.61 ± 0.07 mM-1s-1of Gd(III)-DTPA-bis(Met) 在 pH 7.4 和 7T下被检测。 Eu(III)-DTPA-bis(Met) 的光亮和局部荧光在标准显微镜下观察,位移研究表明配体功能。 Eu(III)-DTPA-bis(Met) 在U-87MG cells中的 KD值为17.3 pM,显示在细胞内有明显的荧光。放射HPLC显示68Ga(III)-DTPA-bis(Met) 的放射化学纯度超过 95% (具体活力 = 400-500 MBq/μmol, 标记效能 78 %)。用68Ga(III)-DTPA-bis(Met)和未标记的L-蛋氨酸对移植瘤的U-87MG无胸腺鼠的预处理使在Micro PET中的肿瘤摄入减少10倍。这些数据支持 68Ga(III)-DTPA-bis(Met)和 LAT1转运蛋白的特定绑定。总之,这种药物在生物环境中具有高度稳定性,并与在肿瘤区域高度积累的、高肿瘤/非肿瘤比率和体内非特定存留的LAT1转运蛋白间具有有效的相互作用。
关键词: 荧光,镧系,LAT1,蛋氨酸,PET成像。
图形摘要
Current Cancer Drug Targets
Title:LAT1 Targeted Delivery of Methionine Based Imaging Probe Derived from M(III) Metal Ions for Early Diagnosis of Proliferating Tumours using Molecular Imaging Modalities
Volume: 14 Issue: 9
Author(s): Puja Panwar Hazari, Surbhi Prakash, Virendra K. Meena, Ambika Jaswal, Harleen Khurana, Surabhi Kirti Mishra, Hemanth kumar Somu Bhonsle, Lokendra Singh and Anil K. Mishra
Affiliation:
关键词: 荧光,镧系,LAT1,蛋氨酸,PET成像。
摘要: We investigated the potential of DTPA-bis(Methionine), a target specific amino acid based probe for detection of L-type amino acid transporters (LAT1) known to over express in proliferating tumours using multimodality imaging. The ligand, DTPA-bis(Met) was readily converted to lanthanide complexes and was found capable of targeting cancer cells using multimodality imaging. DTPA-bis(Met) complexes were synthesized and characterized by mass spectroscopy. MR longitudinal relaxivity, r1=4.067 ± 0.31 mM-1s-1 and transverse relaxivity, r2= 8.61 ± 0.07 mM-1s-1of Gd(III)-DTPA-bis(Met) were observed at pH 7.4 at 7T. Bright, localized fluorescence of Eu(III)-DTPA-bis(Met) was observed with standard microscopy and displacement studies indicated ligand functionality. KD value determined for Eu(III)-DTPA-bis(Met) on U-87MG cells was found to be 17.3 pM and showed appreciable fluorescence within the cells. Radio HPLC showed a radiochemical purity more than 95% (specific activity = 400-500 MBq/μmol, labelling efficiency 78 %) for 68Ga(III)-DTPA-bis(Met). Pre-treatment of xenografted U-87MG athymic mice with 68Ga(III)-DTPA-bis(Met) following unlabelled L-methionine administration reduced tumour uptake by 10-folds in Micro PET. These data support the specific binding of 68Ga(III)-DTPA-bis(Met) to the LAT1 transporter. To summarize, this agent possesses high stability in biological environment and exhibits effective interaction with its LAT1 transporters giving high accumulation in tumour area, excellent tumour/non-tumour ratio and low non-specific retention in vivo.
Export Options
About this article
Cite this article as:
Puja Panwar Hazari , Surbhi Prakash , Virendra K. Meena , Ambika Jaswal , Harleen Khurana , Surabhi Kirti Mishra , Hemanth kumar Somu Bhonsle , Lokendra Singh and Anil K. Mishra , LAT1 Targeted Delivery of Methionine Based Imaging Probe Derived from M(III) Metal Ions for Early Diagnosis of Proliferating Tumours using Molecular Imaging Modalities, Current Cancer Drug Targets 2014; 14 (9) . https://dx.doi.org/10.2174/1568009614666141020102337
DOI https://dx.doi.org/10.2174/1568009614666141020102337 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Transient Receptor Potential Channels in Human Platelets: Expression and Functional Role
Current Molecular Medicine LGI1 Affects Survival of Neuroblastoma Cells by Inhibiting Signalling through Phosphoinositide 3-Kinase
Current Signal Transduction Therapy Synthesis of Arylpiperazine Derivatives as Protease Activated Receptor 1 Antagonists and Their Evaluation as Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer
Current Medicinal Chemistry Adenovirus-based Immunotherapy for Prostate Cancer
Current Cancer Therapy Reviews Semaphorins at the Interface of Development and Cancer
Current Drug Targets Targeting Apoptosis Pathways in Cancer Therapy
Current Cancer Drug Targets Molecular Probing and Imaging of Histone Deacetylase Inhibitors in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: Nongenomic Effects of Thyroid Hormones in Central Nervous System and Skeletal Muscle (Guest Editor: Sandra Incerpi)]
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Signaling Pathways Underpinning the Manifestations of Ionizing Radiation-Induced Bystander Effects
Current Molecular Pharmacology Targeting the Ubiquitin Proteasome System: Beyond Proteasome Inhibition
Current Pharmaceutical Design Research Advances in the Treatment of Melanoma by Treat Melanoma
Current Topics in Medicinal Chemistry Novel Approaches to Cancer Therapy Using Oncolytic Viruses
Current Molecular Medicine Cellular Photodynamic Toxicity of Hematoporphyrin in Various Nanocarrier Systems
Current Nanoscience P-gp Inhibition-Based Strategies for Modulating Pharmacokinetics of Anticancer Drugs: An Update
Current Drug Metabolism Editorial (Thematic Issue: Implication of Non-coding RNAs in Cancer Biology and Cellular Physiology)
Current Genomics The Use of Inorganic Compounds in Photodynamic Therapy: Improvements in Methods and Photosensitizer Design
Recent Patents on Nanotechnology One Hundred Faces of Cyclopamine
Current Pharmaceutical Design The Role of the Endocannabinoid System in Alzheimers Disease: Facts and Hypotheses
Current Pharmaceutical Design